Newron Expands ENIGMA-TRS 2 Enrollment Outside U.S.
MILAN, Italy and MORRISTOWN, N.J. September 25, 2026 — Newron Pharmaceuticals announced that the U.S. clinical hold on enrollment...
Psychiatry
Advertisement
Johnson & Johnson Reports Positive CAPLYTA Phase 3 Data
Titusville, New Jersey, U.S., September 21, 2026 Johnson & Johnson has announced positive topline results from a pivotal Phase...
Otsuka Reports Phase 3b SIMTRIYO Data in ADHD and Anxiety
PRINCETON, N.J. and TOKYO, Japan — September 18, 2026 Otsuka Pharmaceutical presented new Phase 3b results for SIMTRIYO® (centanafadine)...
Johnson & Johnson Reports Positive CAPLYTA Phase 3 Mania Data
Titusville, New Jersey, U.S., September 21, 2026 Johnson & Johnson has announced positive topline results from a pivotal Phase...
Teva Study Examines Treatment Selection in Schizophrenia
Tel Aviv, Israel, September 18, 2026 Teva Pharmaceuticals has announced new findings from a study examining the factors that...
Advertisements
Antengene Advances ATG-022 Into Phase III Gastric Cancer Study
Shanghai and Hong Kong, PRC, September 21, 2026 Antengene Corporation Limited has announced the dosing of the first patient...
Teva Reports New TEV-749 Olanzapine LAI Clinical Data
Tel Aviv, Israel, September18, 2026 Teva Pharmaceutical Industries Ltd. has announced new post hoc clinical data for TEV-‘749, its...
AbbVie Reports New Real-World VRAYLAR Data in Depression
North Chicago, Illinois, September 18, 2026 AbbVie has announced new real-world data for VRAYLAR® (cariprazine) presented at Psych Congress...
Compass Pathways Launches Change the Tune in TRD
LONDON and NEW YORK — September 15, 2026 Compass Pathways plc announced the launch of Change the Tune in...
NRx Pharmaceuticals Deploys Robotic TMS Across HOPE Clinics
WILMINGTON, Del. — September 11, 2026 NRx Pharmaceuticals, Inc. announced that its subsidiary HOPE Therapeutics has begun training and...
Advertisement
